Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Publisher Name » GlobalData
Published Date » 2012-07-02
No. Of Pages » 56
GlobalData, the industry analysis specialist, has released its new report, Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Toxoplasmosis Therapeutics market. The report identifies the key trends shaping and driving the global Toxoplasmosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Toxoplasmosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Toxoplasmosis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Toxoplasmosis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Toxoplasmosis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Toxoplasmosis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Toxoplasmosis Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Toxoplasmosis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Toxoplasmosis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Whats the next big thing in the global Toxoplasmosis Therapeutics market landscape? Identify, understand and capitalize.
Table of Contents
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Toxoplasmosis Therapeutics - Introduction 6
2.1 Disease Overview 6
2.1.1 Types of Toxoplasma gondii Strain 7
2.1.2 Life Cycle and Transmission 7
2.2 Epidemiology 7
2.2.1 Historic Epidemiology (20062011) 8
2.2.2 Forecast Epidemiology (20112019) 9
2.3 Etiology 10
2.3.1 Food-borne Transmission 10
2.3.2 Congenital Transmission 10
2.3.3 Zoonotic Transmission 10
2.3.4 Rare Instances of Transmission 10
2.4 Pathophysiology 10
2.5 Signs and Symptoms 11
2.6 Commonly Used Diagnostic Tests 12
2.6.1 Types of Diagnostic Test 12
2.7 Treatment and Management Options for Toxoplasmosis 13
2.7.1 Management of Toxoplasmosis Infection during Gestation 14
2.7.2 Congenital Toxoplasmosis 14
2.7.3 Ocular Toxoplasmosis 15
2.7.4 Toxoplasmosis in Immunocompetent Patients 15
2.8 GlobalData Pipeline Report Guidance 16
3 Toxoplasmosis Therapeutics - Market Characterization 17
3.1 Toxoplasmosis Therapeutics Market Size (20062011) Global 17
3.2 Toxoplasmosis Therapeutics Market Forecast (20112019) Global 19
3.3 Toxoplasmosis Therapeutics Market Size (20062011) The US 20
3.4 Toxoplasmosis Therapeutics Market Forecast (20112019) The US 21
3.5 Toxoplasmosis Therapeutics Market Size (20062011) France 22
3.6 Toxoplasmosis Therapeutics Market Forecast (20112019) France 23
3.7 Toxoplasmosis Therapeutics Market Size (20062011) Germany 24
3.8 Toxoplasmosis Therapeutics Market Forecast (20112019) Germany 25
3.9 Toxoplasmosis Therapeutics Market Size (20062011) Italy 26
3.10 Toxoplasmosis Therapeutics Market Forecast (20112019) Italy 27
3.11 Toxoplasmosis Therapeutics Market Size (20062011) Spain 28
3.12 Toxoplasmosis Therapeutics Market Forecast (20112019) Spain 29
3.13 Toxoplasmosis Therapeutics Market Size (20062011) The UK 30
3.14 Toxoplasmosis Therapeutics Market Forecast (20112019) The UK 31
3.15 Toxoplasmosis Therapeutics Market Size (20062011) Japan 32
3.16 Toxoplasmosis Therapeutics Market Forecast (20112019) Japan 33
3.17 Drivers and Barriers for the Toxoplasmosis Therapeutics Market 34
3.17.1 Drivers for the Toxoplasmosis Therapeutics Market 34
3.17.2 Barriers for the Toxoplasmosis Therapeutics Market 34
3.18 Opportunity and Unmet Need Analysis 35
3.19 Key Takeaway 36
4 Toxoplasmosis Therapeutics - Competitive Assessment 37
4.1 Overview 37
4.2 Strategic Competitor Assessment 37
4.3 Product Profiles of the Marketed Products in the Toxoplasmosis Therapeutics Market 38
4.3.1 Daraprim (pyrimethamine) 38
4.3.2 Spiramycin 39
4.3.3 Sulfadiazine 39
4.3.4 Folinic Acid 40
4.4 Key Takeaway 40
5 Toxoplasmosis Therapeutics - Pipeline Assessment 41
5.1 Overview 41
5.2 Strategic Pipeline Assessment 41
5.2.1 Toxoplasmosis Therapeutics Phase III Clinical Pipeline 41
5.3 Key Takeaway 41
6 Toxoplasmosis Therapeutics - Clinical Trial Mapping 42
6.1 Clinical Trials by Region and Country 42
6.2 Clinical Trials by Phase 43
6.3 Clinical Trials by Trial Status 44
6.4 Clinical Trial Mapping by Sponsors 45
6.5 Prominent Sponsors 46
6.6 Companies Participating in Toxoplasmosis Therapeutics Clinical Trials 46
7 Toxoplasmosis Therapeutics - Strategic Assessment 47
7.1 Key Events Impacting the Future Market 47
7.2 Toxoplasmosis Therapeutics: Implications for Future Market Competition 47
8 Toxoplasmosis Therapeutics Market - Licensing and Partnership Deals 48
9 Toxoplasmosis Therapeutics Market - KOL Insights, 2012 49
10 Toxoplasmosis Therapeutics - Appendix 50
10.1 Market Definitions 50
10.2 Acronyms 50
10.3 Bibliography 50
10.4 Research Methodology 52
10.4.1 Coverage 52
10.4.2 Secondary Research 52
10.4.3 Forecasting 53
10.4.4 Primary Research 55
10.4.5 Expert Panel Validation 56
10.5 Contact Us 56
10.6 Disclaimer 56
Table 1: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2006-2011 8
Table 2: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2011-2019 9
Table 3: Alternative Antibiotics Used in Ocular Toxoplasmosis 15
Table 4: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011 18
Table 5: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 2011-2019 19
Table 6: Toxoplasmosis Therapeutics Market, The US, Revenue ($m), 2006-2011 20
Table 7: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2011-2019 21
Table 8: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 2006-2011 22
Table 9: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 2011-2019 23
Table 10: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 24
Table 11: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 2011-2019 25
Table 12: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 26
Table 13: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 2011-2019 27
Table 14: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 28
Table 15: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 2011-2019 29
Table 16: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 30
Table 17: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 2011-2019 31
Table 18: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 32
Table 19: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 2011-2019 33
Table 20: Toxoplasmosis Therapeutics-Phase III Pipeline, 2012 41
Table 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012 42
Table 22: Toxoplasmosis Therapeutics - Clinical Trials by Phase, 2012 43
Table 23: Toxoplasmosis Therapeutics - Clinical Trials by Status, 2012 44
Table 24: Toxoplasmosis Therapeutics - Overall Sponsors, 2012 45
Table 25: Toxoplasmosis Therapeutics - Prominent Sponsors, 2012 46
Table 26: Toxoplasmosis Therapeutics - Company Participating in Therapeutics Clinical Trials, 2012 46
Table 27: Toxoplasmosis-Global, Deals, 2012 48
Table 28: Toxoplasmosis Therapeutics Market, Global, KOL Insights, 2012 49
Figure 1: Diagnosis Algorithm for Congenital Toxoplasmosis 12
Figure 2: Approaches for the Treatment of Pregnant Women 14
Figure 3: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011 18
Figure 4: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 20112019 19
Figure 5: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 20062011 20
Figure 6: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 20112019 21
Figure 7: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 20062011 22
Figure 8: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 20112019 23
Figure 9: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 20062011 24
Figure 10: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 20112019 25
Figure 11: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 20062011 26
Figure 12: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 20112019 27
Figure 13: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 20062011 28
Figure 14: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 20112019 29
Figure 15: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 20062011 30
Figure 16: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 20112019 31
Figure 17: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 20062011 32
Figure 18: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 20112019 33
Figure 19: Opportunity and Unmet Need in the Toxoplasmosis Therapeutics Market 36
Figure 20: Toxoplasmosis Therapeutics - Strategic Competitor Assessment, 2012 38
Figure 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012 42
Figure 22: Toxoplasmosis Therapeutics Clinical Trials by Phase, 2012 43
Figure 23: Toxoplasmosis Therapeutics Clinical Trials by Status, 2012 44
Figure 24: Toxoplasmosis Therapeutics Overall Sponsors, 2012 45
Figure 25: Toxoplasmosis Therapeutics Market, Drivers and Barriers, 2012 47
Figure 26: Implications for Future Market Competition in the Toxoplasmosis Therapeutics Market, 2012 47
Figure 27: GlobalData Market Size Estimation 53
Figure 28: GlobalData Market Forecasting Model 55
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Toxoplasmosis Therapeutics - Introduction 6
2.1 Disease Overview 6
2.1.1 Types of Toxoplasma gondii Strain 7
2.1.2 Life Cycle and Transmission 7
2.2 Epidemiology 7
2.2.1 Historic Epidemiology (20062011) 8
2.2.2 Forecast Epidemiology (20112019) 9
2.3 Etiology 10
2.3.1 Food-borne Transmission 10
2.3.2 Congenital Transmission 10
2.3.3 Zoonotic Transmission 10
2.3.4 Rare Instances of Transmission 10
2.4 Pathophysiology 10
2.5 Signs and Symptoms 11
2.6 Commonly Used Diagnostic Tests 12
2.6.1 Types of Diagnostic Test 12
2.7 Treatment and Management Options for Toxoplasmosis 13
2.7.1 Management of Toxoplasmosis Infection during Gestation 14
2.7.2 Congenital Toxoplasmosis 14
2.7.3 Ocular Toxoplasmosis 15
2.7.4 Toxoplasmosis in Immunocompetent Patients 15
2.8 GlobalData Pipeline Report Guidance 16
3 Toxoplasmosis Therapeutics - Market Characterization 17
3.1 Toxoplasmosis Therapeutics Market Size (20062011) Global 17
3.2 Toxoplasmosis Therapeutics Market Forecast (20112019) Global 19
3.3 Toxoplasmosis Therapeutics Market Size (20062011) The US 20
3.4 Toxoplasmosis Therapeutics Market Forecast (20112019) The US 21
3.5 Toxoplasmosis Therapeutics Market Size (20062011) France 22
3.6 Toxoplasmosis Therapeutics Market Forecast (20112019) France 23
3.7 Toxoplasmosis Therapeutics Market Size (20062011) Germany 24
3.8 Toxoplasmosis Therapeutics Market Forecast (20112019) Germany 25
3.9 Toxoplasmosis Therapeutics Market Size (20062011) Italy 26
3.10 Toxoplasmosis Therapeutics Market Forecast (20112019) Italy 27
3.11 Toxoplasmosis Therapeutics Market Size (20062011) Spain 28
3.12 Toxoplasmosis Therapeutics Market Forecast (20112019) Spain 29
3.13 Toxoplasmosis Therapeutics Market Size (20062011) The UK 30
3.14 Toxoplasmosis Therapeutics Market Forecast (20112019) The UK 31
3.15 Toxoplasmosis Therapeutics Market Size (20062011) Japan 32
3.16 Toxoplasmosis Therapeutics Market Forecast (20112019) Japan 33
3.17 Drivers and Barriers for the Toxoplasmosis Therapeutics Market 34
3.17.1 Drivers for the Toxoplasmosis Therapeutics Market 34
3.17.2 Barriers for the Toxoplasmosis Therapeutics Market 34
3.18 Opportunity and Unmet Need Analysis 35
3.19 Key Takeaway 36
4 Toxoplasmosis Therapeutics - Competitive Assessment 37
4.1 Overview 37
4.2 Strategic Competitor Assessment 37
4.3 Product Profiles of the Marketed Products in the Toxoplasmosis Therapeutics Market 38
4.3.1 Daraprim (pyrimethamine) 38
4.3.2 Spiramycin 39
4.3.3 Sulfadiazine 39
4.3.4 Folinic Acid 40
4.4 Key Takeaway 40
5 Toxoplasmosis Therapeutics - Pipeline Assessment 41
5.1 Overview 41
5.2 Strategic Pipeline Assessment 41
5.2.1 Toxoplasmosis Therapeutics Phase III Clinical Pipeline 41
5.3 Key Takeaway 41
6 Toxoplasmosis Therapeutics - Clinical Trial Mapping 42
6.1 Clinical Trials by Region and Country 42
6.2 Clinical Trials by Phase 43
6.3 Clinical Trials by Trial Status 44
6.4 Clinical Trial Mapping by Sponsors 45
6.5 Prominent Sponsors 46
6.6 Companies Participating in Toxoplasmosis Therapeutics Clinical Trials 46
7 Toxoplasmosis Therapeutics - Strategic Assessment 47
7.1 Key Events Impacting the Future Market 47
7.2 Toxoplasmosis Therapeutics: Implications for Future Market Competition 47
8 Toxoplasmosis Therapeutics Market - Licensing and Partnership Deals 48
9 Toxoplasmosis Therapeutics Market - KOL Insights, 2012 49
10 Toxoplasmosis Therapeutics - Appendix 50
10.1 Market Definitions 50
10.2 Acronyms 50
10.3 Bibliography 50
10.4 Research Methodology 52
10.4.1 Coverage 52
10.4.2 Secondary Research 52
10.4.3 Forecasting 53
10.4.4 Primary Research 55
10.4.5 Expert Panel Validation 56
10.5 Contact Us 56
10.6 Disclaimer 56
List of Tables
Table 1: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2006-2011 8
Table 2: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2011-2019 9
Table 3: Alternative Antibiotics Used in Ocular Toxoplasmosis 15
Table 4: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011 18
Table 5: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 2011-2019 19
Table 6: Toxoplasmosis Therapeutics Market, The US, Revenue ($m), 2006-2011 20
Table 7: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2011-2019 21
Table 8: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 2006-2011 22
Table 9: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 2011-2019 23
Table 10: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 24
Table 11: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 2011-2019 25
Table 12: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 26
Table 13: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 2011-2019 27
Table 14: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 28
Table 15: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 2011-2019 29
Table 16: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 30
Table 17: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 2011-2019 31
Table 18: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 32
Table 19: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 2011-2019 33
Table 20: Toxoplasmosis Therapeutics-Phase III Pipeline, 2012 41
Table 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012 42
Table 22: Toxoplasmosis Therapeutics - Clinical Trials by Phase, 2012 43
Table 23: Toxoplasmosis Therapeutics - Clinical Trials by Status, 2012 44
Table 24: Toxoplasmosis Therapeutics - Overall Sponsors, 2012 45
Table 25: Toxoplasmosis Therapeutics - Prominent Sponsors, 2012 46
Table 26: Toxoplasmosis Therapeutics - Company Participating in Therapeutics Clinical Trials, 2012 46
Table 27: Toxoplasmosis-Global, Deals, 2012 48
Table 28: Toxoplasmosis Therapeutics Market, Global, KOL Insights, 2012 49
List of Figures
Figure 1: Diagnosis Algorithm for Congenital Toxoplasmosis 12
Figure 2: Approaches for the Treatment of Pregnant Women 14
Figure 3: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011 18
Figure 4: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 20112019 19
Figure 5: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 20062011 20
Figure 6: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 20112019 21
Figure 7: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 20062011 22
Figure 8: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 20112019 23
Figure 9: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 20062011 24
Figure 10: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 20112019 25
Figure 11: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 20062011 26
Figure 12: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 20112019 27
Figure 13: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 20062011 28
Figure 14: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 20112019 29
Figure 15: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 20062011 30
Figure 16: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 20112019 31
Figure 17: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 20062011 32
Figure 18: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 20112019 33
Figure 19: Opportunity and Unmet Need in the Toxoplasmosis Therapeutics Market 36
Figure 20: Toxoplasmosis Therapeutics - Strategic Competitor Assessment, 2012 38
Figure 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012 42
Figure 22: Toxoplasmosis Therapeutics Clinical Trials by Phase, 2012 43
Figure 23: Toxoplasmosis Therapeutics Clinical Trials by Status, 2012 44
Figure 24: Toxoplasmosis Therapeutics Overall Sponsors, 2012 45
Figure 25: Toxoplasmosis Therapeutics Market, Drivers and Barriers, 2012 47
Figure 26: Implications for Future Market Competition in the Toxoplasmosis Therapeutics Market, 2012 47
Figure 27: GlobalData Market Size Estimation 53
Figure 28: GlobalData Market Forecasting Model 55
Upcoming Reports:
|
Bio-Based Organic Acids Market - Global Industry Analysis, Size, Share, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Since the last decade, the demand for bio-based organic acids is growing at a steady pace owing to the impact of conventional organic acids on the environment. In order to cater to this growing demand, more and more organic acid is being produced from renewable sources such as feedstock.
The market for organic acid synthesized from renewable raw material is also driven by the stringent regulations imposed by regulatory bodies of various nations on conventional organic acid producers. Bio-based alternatives for organic acid are eco-friendly and are frugal compared...
|
|
Functional Foods Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
Rising awareness among consumers towards health benefits of foods and their nutritional benefits for potential disease prevention and health enhancement is driving the global market for functional foods.
Functional foods are the medicinal foods that provide health benefits beyond energy and essential nutrients. They have health promoting and disease preventing properties which are the major reasons for growing preference for functional foods. Growing interest of consumers and widespread understanding of how proper diet can improve immune power are some important...
|
|
Palm Methyl Ester Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Palm methyl ester is a base used for producing biodiesel. It is produced from palm oil in a chemical process is known as transesterification. Methanol acts as a catalyst to convert palm oil to methyl ester. Palm oil cannot be directly used as engine oil due to higher viscosity than that of petroleum products. It is first converted to smaller molecules of methyl ester before being used as a diesel fuel. Palm methyl ester is a ready substitute for diesel. It is successfully tested and used as fuel for power stations and passenger cars. Increasing use of this substitute...
|
Research Assistance
We will be happy to help you find what you need.
Please call us or write us:
Please call us or write us:
866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Email: sales@researchmoz.com
Select License type:
Latest Reports
- The Future of the Wine Market in Indonesia to 2017
- The Future of the Wine Market in Hungary to 2017
- The Future of the Wine Market in Hong Kong to 2017
- The Future of the Wine Market in Greece to 2017
- The Future of the Wine Market in Finland to 2017
- The Future of the Wine Market in Egypt to 2017
- The Future of the Wine Market in Denmark to 2017
- The Future of the Wine Market in Czech Republic to 2017
- The Future of the Wine Market in the United Kingdom to 2017
- Switzerland Quarterly Beverage Tracker Report Q1 2013
Related News
|
One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
|
|
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples.
The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
|
|
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
|
|
Battling against flu, vaccination necessary for health workers
Sep 14, 2012
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease.
Health officials...
|
|
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...
|
